Purchase Order 75N91020P00980

<p>The National Cancer Institute awarded a purchase order to Irepertoire Inc. for $6,525.00 on December 12, 2017, for RNA sequencing services. Performance is located in Bethesda, Maryland. The order is firm-fixed-price with an ultimate completion date of December 29, 2017. Irepertoire Inc. is a small disadvantaged business providing advanced molecular biology and immunological research services, with core expertise in T-cell receptor sequencing and deep immune repertoire analysis.</p>

<p>The National Cancer Institute awarded a purchase order to Irepertoire Inc. for $4,350.00 on March 16, 2018, for AMP2SEQ service MiSeq per library MTAI-M and MTBI-M processing of six samples. Performance occurs in Bethesda, Maryland, with an ultimate completion date of April 30, 2018. Irepertoire Inc. is a small disadvantaged business specializing in molecular biology and immunological research services, including T-cell receptor sequencing and deep immune repertoire analysis.</p>

The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, has awarded a $18,520 purchase order to Irepertoire Inc. to provide T cell samples in order to characterize T cell receptors in helper and cytotoxic T cells. This analysis will allow for the sequencing of millions of T cell receptors and identification of possible structural differences between helper and cytotoxic T cells. Irepertoire will deliver the requested T...

This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Irepertoire Inc., a small disadvantaged business, for RNA sequencing services for mouse T cell receptor research. The contract has a total ceiling value of $13,230.00 and a period of performance through February 28, 2025. Irepertoire Inc. will provide services such as T-cell receptor sequencing,...

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on August 15, 2016, with a ceiling value of $24,163.80 for reagents.</p> <p>Place of performance is Bethesda, MD. The order is firm fixed price with an ultimate completion date of September 14, 2016.</p>

<p>The National Cancer Institute issued a $17,792.10 delivery order to Illumina, Inc. on January 13, 2020, for reagents and consumables.</p> <p>Place of performance is Bethesda, MD 20892. Ultimate completion date is February 12, 2020. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $24,158.08 on October 19, 2017, with an ultimate completion date of November 19, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute awarded a purchase order to Innomics Inc. for $24,449.00 on September 22, 2020, for eukaryotic transcriptome resequencing. Work is performed in Cambridge, Massachusetts, with completion targeted for November 30, 2020. The order is a firm fixed-price acquisition for commercial genomic sequencing and bioinformatics services.</p>

This is a firm fixed price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Irepertoire Inc., a small disadvantaged business, for T-cell receptor sequencing services. The contract has a potential value of $19,404.00 and a completion date of July 26, 2024. Irepertoire Inc. has previously provided a range of services to HHS and other federal agencies, including T-cell receptor...